BNF for Children

22nd May 2023

BNF for Children

This update contains 3 significant changes, 4 dose changes, 1 new monograph, and 1 deleted monograph.

Significant Changes:

• Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measure [MHRA/CHM advice] (see advice in Aromatic inhalations, cough preparations and systemic nasal decongestants).
•  Smallpox and mpox vaccine: updated guidance for immunisation.
• Smallpox vaccine: title changed to Smallpox and mpox vaccine.

Dose Changes:

• Atazanavir [update to dosing for HIV infection when used with low-dose ritonavir].
• Calcipotriol with betamethasone [update to dosing].
• Migalastat [update to include dosing in children from 12 years old].
• Ritonavir [update to dosing for HIV infection when used to increase the effect of atazanavir].

New Monograph:

• Volibris® [ambrisentan].

Deleted Monograph:

• Pholcodine.

11th April 2023

BNF for Children

This update contains 1 significant change, 3 dose changes, 5 new monographs, and 1 deleted monograph.

Significant Change:

• Metolazone (Xaqua®): exercise caution when switching patients between metolazone preparations [MHRA/CHM advice].

Dose Changes:

• Cefotaxime [update to dosing for emergency treatment of suspected bacterial meningitis or meningococcal disease, before urgent transfer to hospital].
• Harvoni® (ledipasvir with sofosbuvir) [update to include dosing in children from 3 years old].
• Sovaldi® (sofosbuvir) [update to include dosing in children from 3 years old].

New Monographs:

• Epclusa® [sofosbuvir with velpatasvir].
• Forxiga® [dapagliflozin].
• Lamzede® [velmanase alfa].
• Nexviadyme® [avalglucosidase alfa].
• Rezurock® [belumosudil].

Deleted Monographs:

• Bleomycin.

14th March 2023

BNF for Children

This update contains 1 significant change, 2 dose changes, 2 new monographs, and 1 new preparation.

Significant Changes:

• Genital system infections, antibacterial therapy: updated guidance for the management of uncomplicated genital chlamydia and gonorrhoea.

Dose Change:

• Azithromycin [update to dosing for uncomplicated genital chlamydia in children from 12 years old, and update to include dosing in children from 12 years old for uncomplicated gonorrhoea].
• Ceftriaxone [update to dosing for pelvic inflammatory disease in children from 12 years old, and update to dosing for uncomplicated gonorrhoea and congenital gonococcal conjunctivitis].

New Monographs:

• Tezspire® [tezepelumab].
• Xenpozyme® [olipudase alfa].

New Preparations:

• DuoResp Spiromax® [budesonide with formoterol].

14th February 2023

BNF for Children

This update contains 3 significant changes and 1 dose change.

Significant Changes:

• Dupilumab (Dupixent®): risk of ocular adverse reactions and need for prompt management [MHRA/CHM advice].
• Ibuprofen: updated breast-feeding advice.
• Obesity: updated guidance on management.

Dose Change:

• Crysvita® (burosumab) [update to children’s dosing].

10th January 2023

BNF for Children

This update contains 2 significant changes, 1 dose change, 2 new monographs and 1 new preparation.

Significant Changes:

• Contraceptives, interactions: updated guidance.
• Oropharyngeal infections, antibacterial therapy: updated guidance for the management of acute sore throat.

Dose Changes:

• Dupixent® (dupilumab) [update to include dosing in children from 6 years old for severe asthma with type 2 inflammation].

New Monographs:

• Drovelis® [drospirenone with estetrol].
• Lucentis® [ranibizumab].

New Preparation:

• Efmody® [hydrocortisone].

31st December 2022

BNF for Children

This update contains 2 significant changes, 3 dose changes, 2 new monographs and 2 new preparations.

Significant Changes:

• Herpesvirus infections: updated guidance for post-exposure prophylaxis
• Melatonin (Adaflex®, Ceyesto®): new indication for insomnia in patients with ADHD

Dose Changes:

• Budesonide [update to dosing for intranasal administration for rhinitis and nasal polyps]
• Lacosamide [update to age range for monotherapy and adjunctive treatment of focal seizures with or without secondary generalisation]
• Naloxone hydrochloride [update to neonatal dosing]

New Monographs:

• Imcivree® [setmelanotide]
• Oxbryta® [voxelotor]

New Preparations:

• Actimorph® [morphine]
• Dificlir® [fidaxomicin]

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes